List of Excipients in Branded Drug HYCET

Generic Drugs Containing HYCET

Company	Ingredient	NDC	Excipient
G&W Laboratories Inc	hydrocodone bitartrate and acetaminophen	0713-0703	ANHYDROUS CITRIC ACID
G&W Laboratories Inc	hydrocodone bitartrate and acetaminophen	0713-0703	D&C RED NO. 33
G&W Laboratories Inc	hydrocodone bitartrate and acetaminophen	0713-0703	ETHYL MALTOL
G&W Laboratories Inc	hydrocodone bitartrate and acetaminophen	0713-0703	FD&C RED NO. 40
G&W Laboratories Inc	hydrocodone bitartrate and acetaminophen	0713-0703	GLYCERIN

What are the Most Frequently-Used Excipients in HYCET?

# Of NDCs	Excipient
1	ANHYDROUS CITRIC ACID
1	D&C RED NO. 33
1	ETHYL MALTOL
1	FD&C RED NO. 40
1	GLYCERIN

HYCET Excipient Strategy and Commercial Opportunities

Last updated: September 14, 2026

HYCET is an oral solution containing hydrocodone bitartrate and acetaminophen, commonly labeled at 7.5 mg hydrocodone and 325 mg acetaminophen per 15 mL. Its commercial value is driven less by active-ingredient exclusivity than by reliable liquid manufacturing, taste control, dosing safety, supply continuity, and compliance with opioid regulations. The strongest excipient opportunities are alcohol-free and sugar-reduced formulations, improved taste masking, preservative optimization, unit-dose packaging, and manufacturing platforms that reduce diversion and dosing errors.

What is HYCET and which dosage form does it use?

HYCET is a prescription oral solution for the management of pain severe enough to require an opioid analgesic when alternative treatments are inadequate. The product combines hydrocodone, a Schedule II opioid, with acetaminophen. FDA labeling warns that acetaminophen-containing products create a risk of severe liver injury when the total daily dose exceeds recommended limits.[1]

Attribute	HYCET profile
Active ingredients	Hydrocodone bitartrate and acetaminophen
Dosage form	Oral solution
Labeled strength	7.5 mg hydrocodone and 325 mg acetaminophen per 15 mL
Route	Oral
Therapeutic category	Opioid analgesic
Controlled-substance status	Schedule II
Primary formulation risks	Taste, dose measurement, chemical stability, microbial control, opioid diversion
Primary commercial alternatives	Hydrocodone/acetaminophen tablets, capsules, oral solutions, and other opioid analgesics
Key regulatory risks	Opioid labeling, pediatric restrictions, acetaminophen toxicity, abuse deterrence, controlled-substance distribution

HYCET’s liquid format creates access advantages for patients who cannot swallow tablets. It also creates higher formulation and packaging risk because every dose must deliver two actives uniformly over the product shelf life.

What excipients are used in HYCET oral solution?

The HYCET formulation uses excipients associated with sweetness, viscosity, pH control, preservation, solubilization, color, and flavor. FDA labeling identifies inactive ingredients that include water, glycerin, propylene glycol, sodium benzoate, citric acid, sodium citrate, sucrose, alcohol, flavoring components, and colorants.[1]

The exact excipient profile can vary by approved product presentation and manufacturing source. The functional roles are more commercially important than the individual ingredients.

Excipient function	Likely formulation role in HYCET
Purified water	Primary vehicle
Glycerin	Sweetness, mouthfeel, viscosity, cosolvent function
Propylene glycol	Solubilization and flavor delivery
Alcohol	Cosolvent and possible preservative-support function
Sucrose	Sweetness and taste masking
Sodium benzoate	Antimicrobial preservation
Citric acid and sodium citrate	pH adjustment and buffering
Flavor system	Suppression of hydrocodone and acetaminophen bitterness
Colorant	Product identification and patient acceptability

The principal technical challenge is taste. Hydrocodone and acetaminophen each contribute bitterness, while the combination can leave a persistent aftertaste. Sugar, flavor, glycerin, propylene glycol, and buffer selection must work together. Increasing sweetness alone may not adequately mask the opioid component.

How does excipient selection affect HYCET product performance?

Excipient selection affects five commercial performance criteria: dose uniformity, chemical stability, microbial stability, patient acceptance, and manufacturing reproducibility.

Taste masking

Taste masking is the highest-value formulation target. A successful system must suppress immediate bitterness and reduce lingering aftertaste without requiring excessive sugar or alcohol. Potential approaches include:

• High-impact flavor systems using fruit, berry, citrus, or confectionery profiles
• Ion-pairing or complexation of hydrocodone
• Polymer-based taste-masking systems
• Microencapsulation or coated drug particles
• pH optimization to reduce free bitter drug species
• Sweetener combinations using sucrose, sucralose, acesulfame potassium, or polyols

Taste-masking technology must preserve rapid oral-solution performance. Excessive particle coating or complexation can create dose-uniformity, sedimentation, or dissolution concerns.

Solubilization and physical stability

Hydrocodone salts are water-soluble, but the combined formulation still requires control of pH, ionic strength, flavor oils, and preservative compatibility. Propylene glycol and alcohol may help dissolve flavor components and reduce precipitation. The formulation must remain clear or acceptably uniform throughout shelf life.

Commercial developers should test:

• pH drift during accelerated stability
• Precipitation after temperature cycling
• Interaction between flavor oils and preservatives
• Adsorption to plastic bottles and oral syringes
• Compatibility with dosing cups and metering devices
• Uniformity after repeated opening

Preservative strategy

Sodium benzoate provides a familiar preservation platform, but its effectiveness depends on pH. Developers must establish antimicrobial effectiveness in the final formulation rather than assume performance from the individual ingredient.

Commercial differentiation is possible through:

• Preservative concentration optimization
• Lower-benzoate formulations
• Alternative preservative systems
• Single-use or unit-dose packaging that reduces multidose contamination
• Packaging that limits microbial ingress

Any reformulation must address preservative efficacy, extractables and leachables, and container-closure integrity.

Sugar reduction

Sucrose improves taste but increases concern for patients with diabetes, dental disease, or dietary restrictions. A sugar-reduced or sugar-free HYCET alternative could improve institutional and retail positioning.

Potential replacements include:

• Sucralose
• Acesulfame potassium
• Saccharin
• Sorbitol
• Xylitol
• Maltitol
• Glycerin-based sweetness systems

Polyols can introduce gastrointestinal tolerability issues and may alter viscosity. High-intensity sweeteners can create a delayed or metallic aftertaste, making flavor architecture critical.

Alcohol reduction or elimination

Alcohol can support solubilization and flavor delivery but creates patient, caregiver, and institutional concerns. An alcohol-free formulation would have potential advantages for pediatric-adjacent settings, substance-use-risk populations, religious or dietary preferences, and hospital formularies.

Removing alcohol may require:

• Higher propylene glycol or glycerin levels
• Alternative flavor solvents
• Emulsification or solubilization technology
• New preservative optimization
• Reassessment of microbial stability
• New extractables and leachables studies

Because HYCET is an opioid, an alcohol-free product would not eliminate controlled-substance restrictions. It could, however, improve formulary acceptance and reduce avoidable excipient objections.

What formulation patents could protect an improved HYCET product?

The original HYCET formulation has limited apparent long-term exclusivity value because hydrocodone/acetaminophen oral solutions are established products and generic competition can rely on the 505(j) ANDA pathway when the reference product is commercially and regulatorily available.

A differentiated formulation could support new patent claims around:

1. A specific taste-masking complex or coated particle.
2. A defined excipient ratio producing improved stability.
3. A sugar-free and alcohol-free oral solution.
4. A preservative system with a defined pH range.
5. A low-sedimentation or no-shake formulation.
6. A unit-dose container that improves dosing accuracy.
7. A tamper-evident or diversion-resistant delivery system.
8. A manufacturing process that improves content uniformity.
9. A flavor system that reduces hydrocodone aftertaste.
10. A metering package integrated with the formulation.

Patent value would depend on claim breadth, freedom-to-operate analysis, design-around risk, and demonstrated clinical or manufacturing advantages. A patent directed only to routine substitution of one sweetener for another would likely face substantial obviousness risk. Stronger claims would connect a defined excipient system to measurable stability, taste, dose-uniformity, or abuse-deterrence performance.

When does HYCET lose exclusivity and how exposed is it to generics?

HYCET does not have the commercial profile of a product protected by an active-ingredient patent. Hydrocodone and acetaminophen are well-established active ingredients, and oral hydrocodone/acetaminophen products have long faced generic competition.

The key commercial issue is whether a current reference-listed product remains available for ANDA comparison and whether competing manufacturers can satisfy FDA requirements for the same strength, dosage form, route, labeling, and inactive-ingredient compatibility. FDA Orange Book status should be assessed by product-specific NDA and listed patents or exclusivity codes rather than by the brand name alone.[2]

Protection category	HYCET exposure
Composition-of-matter patent	Low, because the actives are established
Basic oral-solution formulation	Low to moderate
Method-of-use protection	Limited practical value for established opioid pain indications
Regulatory exclusivity	Product-specific and likely limited compared with new chemical entities
Generic substitution risk	High
Manufacturing barrier	Moderate, due to controlled-substance handling and liquid-product quality requirements
Differentiated reformulation opportunity	Moderate to high

A new excipient system would not automatically block conventional generic HYCET. It would create a separate product opportunity that may require a new NDA, a supplement, or a 505(b)(2) strategy depending on the extent of formulation and labeling changes.

What FDA pathways apply to a new HYCET formulation?

A manufacturer pursuing a conventional hydrocodone/acetaminophen oral solution would generally consider the ANDA pathway. A manufacturer pursuing a materially different formulation may consider 505(b)(2), particularly where the product relies partly on FDA findings for an approved hydrocodone/acetaminophen product but introduces a new formulation, delivery system, or clinical use.[3]

ANDA opportunity

The ANDA route is most suitable when the proposed product has:

• The same active ingredients
• The same strength
• The same dosage form and route
• Comparable labeling
• Acceptable inactive-ingredient levels
• Demonstrated pharmaceutical equivalence and bioequivalence

The commercial advantage is lower development cost than a full NDA. The disadvantage is limited differentiation and direct price competition.

505(b)(2) opportunity

A 505(b)(2) strategy may support:

• Alcohol-free or sugar-free formulation
• Modified taste profile
• New metering device
• Unit-dose presentation
• New patient population or administration setting
• Alternative concentration with supporting safety data
• New abuse-deterrent or diversion-resistant presentation

The sponsor must manage clinical bridging, labeling differences, pediatric considerations, and potential patent certifications. A new formulation does not avoid opioid scheduling or postmarketing safety obligations.

What manufacturing and IP barriers affect HYCET competitors?

The main barriers are operational rather than molecular.

Controlled-substance manufacturing

Manufacturers must maintain DEA registration, secure hydrocodone inventory, reconcile controlled-substance quantities, and comply with recordkeeping and distribution controls.[4] These requirements increase working-capital needs and limit the number of qualified suppliers.

Liquid manufacturing

A compliant product requires validated mixing, in-process sampling, uniformity testing, microbial control, filling accuracy, and container-closure validation. Oral solutions also have greater shipping and packaging sensitivity than tablets.

Dose-delivery systems

A calibrated oral syringe can reduce dosing variability compared with a household spoon or cup. A manufacturer may obtain commercial and patent value from a proprietary unit-dose package, integrated syringe, or tamper-evident closure. The device must not create usability problems for caregivers or interfere with the product’s labeled dosing instructions.

Acetaminophen risk management

Any product containing acetaminophen must communicate total daily exposure across combination products. Formulation differentiation does not remove the risk of accidental duplicate dosing. Labeling, package design, and dispensing controls therefore have commercial importance.

Which commercial opportunities are strongest for HYCET excipients?

The highest-potential opportunities are differentiated products that solve a specific clinical or dispensing problem.

Opportunity	Commercial rationale	Development burden
Sugar-free oral solution	Expands suitability for restricted diets and institutional formularies	Moderate
Alcohol-free oral solution	Removes an avoidable excipient concern	Moderate to high
Improved taste masking	Supports adherence and caregiver acceptance	Moderate to high
Unit-dose packaging	Limits contamination and improves dosing control	Moderate
Oral-syringe presentation	Reduces measurement errors	Low to moderate
Preservative-optimized product	Supports stability and clean-label positioning	Moderate
Lower-volume concentration	Reduces administration burden	High, due to dosing and safety risks
Abuse-deterrent liquid	Potential differentiation in opioid risk management	High
Contract formulation platform	Enables multiple opioid and non-opioid liquid products	Moderate

Taste masking and alcohol elimination are the most commercially defensible formulation themes. A lower-volume, higher-concentration product may reduce administration burden but could increase overdose risk from measurement errors and accidental ingestion. It would require especially strong human-factors and risk-management evidence.

How does HYCET compare with tablet and capsule competitors?

HYCET’s liquid presentation provides flexibility but carries a higher cost and quality burden than solid oral dosage forms.

Factor	HYCET oral solution	Hydrocodone/acetaminophen tablet
Swallowing flexibility	High	Lower
Dose measurement risk	Higher	Lower
Taste burden	High	Low
Manufacturing complexity	Higher	Lower
Packaging burden	Higher	Lower
Pediatric use	Restricted and clinically limited	Restricted and clinically limited
Institutional utility	Useful for selected patients	Broad
Generic price pressure	High	High
Excipient differentiation	Stronger	More limited

The liquid format is most attractive where swallowing difficulty, dose flexibility, or caregiver administration matters. It is less attractive when low cost, portability, and dosing simplicity dominate.

What is the outlook for HYCET licensing and partnerships?

Licensing opportunities are more likely to arise around formulation and delivery technology than around the HYCET brand itself. Potential partners include:

• Specialty generic manufacturers
• Opioid-focused contract manufacturers
• Excipient and taste-masking technology companies
• Oral-liquid packaging suppliers
• Hospital and long-term-care distributors
• Companies with controlled-substance infrastructure

A valuable deal structure could combine an excipient platform license with manufacturing rights, geographic rights, or a supply agreement. The strongest diligence points are patent ownership, freedom to operate, FDA precedent, controlled-substance quotas, commercial supply capacity, and evidence that the formulation performs better than standard generic oral solutions.

Key Takeaways

• HYCET is a hydrocodone/acetaminophen oral solution whose value depends on formulation execution rather than active-ingredient exclusivity.
• Taste masking is the central excipient challenge.
• Sugar-free and alcohol-free versions offer the clearest differentiation opportunities.
• Unit-dose packaging and oral syringes can reduce contamination and dosing risk.
• Conventional generic competition is strong because the active ingredients and dosage form are established.
• A materially differentiated product may require a 505(b)(2) pathway rather than a simple ANDA.
• Patent opportunities are strongest for defined excipient systems, taste-masking technologies, packaging, manufacturing processes, and dosing-control systems.
• Controlled-substance compliance and liquid-product manufacturing are meaningful barriers to entry.
• Acetaminophen toxicity and opioid diversion remain central regulatory and commercial risks.

FAQs About HYCET Excipient and Commercial Strategy

Can HYCET be reformulated without changing its FDA approval?

Minor excipient changes may be possible through an FDA supplement, but a material change in formulation, concentration, delivery device, labeling, or clinical performance may require a new regulatory strategy.

Is an alcohol-free HYCET formulation commercially attractive?

Yes. It could remove a frequently scrutinized excipient, improve institutional acceptance, and support differentiation from conventional oral solutions. The sponsor would need to solve solubilization, flavor delivery, preservation, and stability requirements.

Can a generic manufacturer copy HYCET’s excipients?

A generic manufacturer generally must meet applicable inactive-ingredient and pharmaceutical-equivalence requirements, but it does not always need to reproduce every excipient in the same qualitative and quantitative composition. FDA review focuses on safety, performance, and equivalence.

Would a taste-masking patent block generic HYCET?

Only if the generic product practices valid, enforceable patent claims. A narrow taste-masking patent may not block conventional products that use a different excipient system or flavor platform.

Is HYCET suitable for pediatric commercialization?

Hydrocodone labeling imposes significant pediatric restrictions, including contraindications for children younger than 12 years and for certain post-tonsillectomy or adenoidectomy patients under 18.[1] A pediatric-oriented commercial strategy would face substantial safety and regulatory constraints.

References

1. U.S. Food and Drug Administration. (n.d.). Hycet (hydrocodone bitartrate and acetaminophen) oral solution prescribing information.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.

3. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2).

4. U.S. Drug Enforcement Administration. (n.d.). Controlled substance schedules and regulatory requirements.